Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition

The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib’s toxicity towards the (central) nervous system. We used standardized neuropsychological testing to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Brain Commun
Autors principals: Huehnchen, Petra, Springer, Andreas, Kern, Johannes, Kopp, Ute, Kohler, Siegfried, Alexander, Tobias, Hiepe, Falk, Meisel, Andreas, Boehmerle, Wolfgang, Endres, Matthias
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425526/
https://ncbi.nlm.nih.gov/pubmed/32954282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/braincomms/fcaa021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars